Cue Biopharma Stock Today
| CUE Stock | USD 0.94 0.11 10.48% |
Performance10 of 100
| Odds Of DistressOver 72
|
Cue Biopharma is trading at 0.94 as of the 13th of December 2024, a 10.48% down since the beginning of the trading day. The stock's lowest day price was 0.94. Cue Biopharma has a very high chance of experiencing financial distress in the next few years of operation. However, it had a very ok returns during the last 90 days. The performance scores are derived for the period starting the 16th of June 2024 and ending today, the 13th of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 2nd of January 2018 | Category Healthcare | Classification Health Care |
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. The company has 63.35 M outstanding shares of which 1 M shares are currently shorted by investors with about 1.54 days to cover. More on Cue Biopharma
Moving against Cue Stock
| 0.66 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Cue Stock Highlights
| CEO Director | MSc JD | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsCue Biopharma can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Cue Biopharma's financial leverage. It provides some insight into what part of Cue Biopharma's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Cue Biopharma (CUE) is traded on NASDAQ Exchange in USA. It is located in 40 Guest Street, Boston, MA, United States, 02135 and employs 53 people. Cue Biopharma is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a total capitalization of 62.11 M. Cue Biopharma runs under Biotechnology sector within Health Care industry. The entity has 63.35 M outstanding shares of which 1 M shares are currently shorted by investors with about 1.54 days to cover.
Cue Biopharma has about 66.13 M in cash with (39.96 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.87, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Cue Biopharma Probability Of Bankruptcy
Ownership AllocationCue Biopharma holds a total of 63.35 Million outstanding shares. Almost 75.87 percent of Cue Biopharma outstanding shares are held by general public with 0.54 (percent) owned by insiders and only 23.59 % by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Cue Ownership Details
Cue Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Bank Of America Corp | 2024-09-30 | 239.2 K | |
| Stifel Financial Corp | 2024-09-30 | 194.2 K | |
| State Street Corp | 2024-09-30 | 177.1 K | |
| Northern Trust Corp | 2024-09-30 | 138.3 K | |
| Jane Street Group Llc | 2024-06-30 | 98.6 K | |
| Hightower Advisors, Llc | 2024-09-30 | 83.3 K | |
| Ubs Group Ag | 2024-09-30 | 74.2 K | |
| Morgan Stanley - Brokerage Accounts | 2024-09-30 | 33.7 K | |
| Xtx Topco Ltd | 2024-09-30 | 27.7 K | |
| Bleichroeder Lp | 2024-09-30 | 5 M | |
| Slate Path Capital Lp | 2024-09-30 | 2.4 M |
Cue Biopharma Historical Income Statement
Cue Stock Against Markets
Cue Biopharma Corporate Management
| JD MSc | CEO Director | Profile | |
| Kenneth MD | Acting Officer | Profile | |
| Steven Almo | CoFounder Board | Profile | |
| Matteo MD | Chief Officer | Profile | |
| Dr III | CoFounder | Profile | |
| Lucinda Warren | Chief Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cue Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. For information on how to trade Cue Stock refer to our How to Trade Cue Stock guide.You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cue Biopharma. If investors know Cue will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cue Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.91) | Revenue Per Share 0.172 | Quarterly Revenue Growth 0.923 | Return On Assets (0.52) | Return On Equity (1.39) |
The market value of Cue Biopharma is measured differently than its book value, which is the value of Cue that is recorded on the company's balance sheet. Investors also form their own opinion of Cue Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Cue Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cue Biopharma's market value can be influenced by many factors that don't directly affect Cue Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cue Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cue Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cue Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.